Logo image of XOMAO

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Fundamental Analysis

NASDAQ:XOMAO - Nasdaq - US98419J4040 - Currency: USD

25.3399  +0.09 (+0.38%)

Fundamental Rating

4

Overall XOMAO gets a fundamental rating of 4 out of 10. We evaluated XOMAO against 559 industry peers in the Biotechnology industry. There are concerns on the financial health of XOMAO while its profitability can be described as average. XOMAO is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year XOMAO has reported negative net income.
In the past year XOMAO has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: XOMAO reported negative net income in multiple years.
In multiple years XOMAO reported negative operating cash flow during the last 5 years.
XOMAO Yearly Net Income VS EBIT VS OCF VS FCFXOMAO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

XOMAO has a Return On Assets of -8.74%. This is amongst the best in the industry. XOMAO outperforms 84.97% of its industry peers.
Looking at the Return On Equity, with a value of -21.96%, XOMAO belongs to the top of the industry, outperforming 83.90% of the companies in the same industry.
XOMAO's Return On Invested Capital of 0.19% is amongst the best of the industry. XOMAO outperforms 91.41% of its industry peers.
Industry RankSector Rank
ROA -8.74%
ROE -21.96%
ROIC 0.19%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAO Yearly ROA, ROE, ROICXOMAO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

XOMAO has a better Operating Margin (1.03%) than 91.77% of its industry peers.
XOMAO does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 1.03%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAO Yearly Profit, Operating, Gross MarginsXOMAO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XOMAO is destroying value.
The number of shares outstanding for XOMAO has been increased compared to 1 year ago.
The number of shares outstanding for XOMAO has been increased compared to 5 years ago.
XOMAO has a worse debt/assets ratio than last year.
XOMAO Yearly Shares OutstandingXOMAO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAO Yearly Total Debt VS Total AssetsXOMAO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -5.97, we must say that XOMAO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XOMAO (-5.97) is worse than 63.51% of its industry peers.
A Debt/Equity ratio of 1.18 is on the high side and indicates that XOMAO has dependencies on debt financing.
The Debt to Equity ratio of XOMAO (1.18) is worse than 78.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF N/A
Altman-Z -5.97
ROIC/WACC0.01
WACC13.3%
XOMAO Yearly LT Debt VS Equity VS FCFXOMAO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

XOMAO has a Current Ratio of 5.54. This indicates that XOMAO is financially healthy and has no problem in meeting its short term obligations.
XOMAO has a Current ratio (5.54) which is comparable to the rest of the industry.
XOMAO has a Quick Ratio of 5.54. This indicates that XOMAO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XOMAO (5.54) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 5.54
XOMAO Yearly Current Assets VS Current LiabilitesXOMAO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.50% over the past year.
The Revenue has grown by 663.79% in the past year. This is a very strong growth!
The Revenue has been growing by 9.17% on average over the past years. This is quite good.
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%

3.2 Future

XOMAO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.94% yearly.
Based on estimates for the next years, XOMAO will show a very strong growth in Revenue. The Revenue will grow by 33.09% on average per year.
EPS Next Y73.1%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
EPS Next 5YN/A
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMAO Yearly Revenue VS EstimatesXOMAO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMAO Yearly EPS VS EstimatesXOMAO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

XOMAO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 591.50, which means the current valuation is very expensive for XOMAO.
87.12% of the companies in the same industry are more expensive than XOMAO, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of XOMAO to the average of the S&P500 Index (22.13), we can say XOMAO is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 591.5
XOMAO Price Earnings VS Forward Price EarningsXOMAO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, XOMAO is valued cheaper than 90.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 264.3
XOMAO Per share dataXOMAO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as XOMAO's earnings are expected to grow with 39.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.15%
EPS Next 3Y39.94%

More info and screens

5

5. Dividend

5.1 Amount

XOMAO has a Yearly Dividend Yield of 8.26%, which is a nice return.
Compared to an average industry Dividend Yield of 110.75, XOMAO pays a better dividend. On top of this XOMAO pays more dividend than 99.46% of the companies listed in the same industry.
XOMAO's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
Industry RankSector Rank
Dividend Yield 8.26%

5.2 History

XOMAO has been paying a dividend for over 5 years, so it has already some track record.
XOMAO has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAO Yearly Dividends per shareXOMAO Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

XOMAO has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-29.44%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
XOMAO Yearly Income VS Free CF VS DividendXOMAO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

More info and screens

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (6/13/2025, 8:00:02 PM)

25.3399

+0.09 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners62.7%
Inst Owner ChangeN/A
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap303.32M
Analysts82
Price Target67.27 (165.47%)
Short Float %0.01%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield 8.26%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-29.44%
Div Incr Years0
Div Non Decr Years3
Ex-Date04-03 2025-04-03 (0.52344)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.13%
Min EPS beat(2)-45.44%
Max EPS beat(2)119.7%
EPS beat(4)2
Avg EPS beat(4)56.23%
Min EPS beat(4)-256.98%
Max EPS beat(4)407.67%
EPS beat(8)3
Avg EPS beat(8)22.51%
EPS beat(12)3
Avg EPS beat(12)-16.39%
EPS beat(16)5
Avg EPS beat(16)-21.54%
Revenue beat(2)1
Avg Revenue beat(2)59.22%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.22%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)22.27%
Revenue beat(12)6
Avg Revenue beat(12)0.36%
Revenue beat(16)7
Avg Revenue beat(16)-7.52%
PT rev (1m)-2.85%
PT rev (3m)-25.69%
EPS NQ rev (1m)-37.92%
EPS NQ rev (3m)-6.56%
EPS NY rev (1m)0%
EPS NY rev (3m)1.59%
Revenue NQ rev (1m)22.56%
Revenue NQ rev (3m)15.48%
Revenue NY rev (1m)36.77%
Revenue NY rev (3m)31.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 591.5
P/S 6.83
P/FCF N/A
P/OCF N/A
P/B 3.58
P/tB 5.12
EV/EBITDA 264.3
EPS(TTM)-1.14
EYN/A
EPS(NY)0.04
Fwd EY0.17%
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS3.71
BVpS7.07
TBVpS4.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.74%
ROE -21.96%
ROCE 0.24%
ROIC 0.19%
ROICexc 0.36%
ROICexgc 0.49%
OM 1.03%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF N/A
Debt/EBITDA 82.05
Cap/Depr 2651.64%
Cap/Sales 45.45%
Interest Coverage 0.04
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 5.54
Altman-Z -5.97
F-Score5
WACC13.3%
ROIC/WACC0.01
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.98%
EPS Next Y73.1%
EPS Next 2Y42.15%
EPS Next 3Y39.94%
EPS Next 5YN/A
Revenue 1Y (TTM)663.79%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%967.92%
Revenue Next Year67.38%
Revenue Next 2Y38.13%
Revenue Next 3Y33.09%
Revenue Next 5YN/A
EBIT growth 1Y102%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.83%
EBIT Next 3Y51.02%
EBIT Next 5YN/A
FCF growth 1Y16.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.67%
OCF growth 3YN/A
OCF growth 5YN/A